NEW: Updated PML risk numbers--1 per 330--
With more than 115,000 patients globally treated with natalizumab (Tysabri) for longer periods of time, that estimate of PML risk is 1 per 330. In patients who test positive for antibodies to JCV, have a clinical history of immune suppressive treatment before natalizumab, and have received more than 24 doses, the number of PML cases is 1 per 90. http://www.ncbi.nlm.nih.gov/pubmed/23925759


Risk factors for rare diseases can be risky to def... [Neurology. 2013] - PubMed - NCBI
www.ncbi.nlm.nih.gov
PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.